Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clairleaf long-term safety and efficacy study of BI 1291583 in non-cystic fibrosis bronchiectasis
jRCT2041230099Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of verducatib in bronchiectasis, sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of treatment-emergent adverse events. Started Dec 2023; status: active, not recruiting.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on jRCT2041230099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230099.